named Steve Gannon chief financial officer, effective April 3.
The Mont-Saint-Hilaire, Quebec, gastroenterology drug maker said its current finance chief, Jean Vezina, will continue to serve in the role of vice president, finance, focusing on "financial reporting excellence and compliance in response to the increasingly complex regulatory and geographical environment."
"We are very pleased to welcome Mr. Gannon to the Axcan team. Steve brings significant capital market experience to the company, which will be invaluable as Axcan moves to the next phase of its growth. We look forward to Steve's contribution to our activities," said CEO Frank Verwiel. "With the growth of the company, Jean Vezina will provide an increased focus on financial reporting excellence and compliance in response to the increasingly complex regulatory and geographical environment."
Gannon has held a number of senior financial roles at AstraZeneca and most recently served as chief financial officer of CryoCath Technologies. Montreal-based CryoCath said Friday that Gannon would leave Feb. 24.
On Friday, Axcan rose a dime to $17.99.